Search


EMA Guidance: Anonymisation and Confidentiality in Risk Management Plans (RMPs)
The European Medicines Agency (EMA)Â has published a revised guideline titled " Guidance on the Anonymisation of Protected Personal Data...

Sharan Murugan
Apr 184 min read
13 views
0 comments


EMA: Guidance on the Anonymisation of PPD & Assessment of CCI during the preparation of RMPs
The European Medicines Agency (EMA) yesterday (26 April, 2024) released an updated guidance on the "Anonymisation of protected personal...

Sharan Murugan
Apr 27, 20242 min read
229 views
0 comments


EMA Guidance: Anonymisation of PPD & CCI - Preparation of Risk Management Plans (RMP)
Today (04-November-2022) European Medicines Agency, released updated guidance on "Anonymisation of Protected Personal Data and assessment...

Sharan Murugan
Nov 4, 20221 min read
300 views
0 comments


USFDA's Guidance on Risk Management Plans to Mitigate Drug Shortages
The USFDA recently released draft guidance intended to help stakeholders develop, maintain, and implement risk management plans (RMPs) to...

Sharan Murugan
May 22, 20221 min read
18 views
0 comments